tbuckley/cabot-search huggingface dataset:
Single Molecule Real-Time Sequencing of the M Protein (SMaRT M-Seq): Toward Personalized Medicine Approaches in Monoclonal Gammopathies
Authors: Pasquale Cascino, Alice Nevone, Claudia Scopelliti, Maria Girelli, Giulia Mazzini, Serena Caminito, Giancarlo Russo, Paolo Milani, Marco Basset, Andrea Foli, Francesca Fazio, Simona Casarini, Margherita Massa, Margherita Bozzola, Jessica Ripepi, Melania Antonietta Sesta, Gloria Acquafredda, Marica De Cicco, Antonia Moretta, Paola Rognoni, Enrico Milan, Stefano Ricagno, Francesca Lavatelli, Maria Teresa Petrucci, Catherine Klersy, Giampaolo Merlini, Giovanni Palladini, Mario Nuvolone
Journal: Blood (2021)
TIRAP Drives Marrow Failure through an Ifnγ-Hmgb1 Axis That Disrupts the Endothelial Niche
Authors: Aparna Gopal, Rawa Ibrahim, Megan Fuller, Patricia Umlandt, Jeremy Parker, Jessica Tran, Linda Ya-Ting Chang, Jeff Lam, Jenny Li, Melody Lu, Aly Karsan
Journal: Blood (2021)
Corrigendum to “Identification of Differential Tumor Subtypes of T1 Bladder Cancer” [Eur. Urol. 78 (2020) 533–537]
Authors: A Gordon Robertson, Clarice S Groeneveld, Brian Jordan, Xiaoqi Lin, Kimberly A McLaughlin, Arighno Das, Leigh Ann Fall, Damiano Fantini, Timothy J Taxter, Lauren S Mogil, Sia Viborg Lindskrog, Lars Dyrskjøt, David J McConkey, Robert S Svatek, Aurélien de Reyniès, Mauro A A Castro, Joshua J Meeks
Journal: European Urology (2021)
<i>In Vivo</i> crispr Screening Identifies GLUT1 As a Key Metabolic Regulator of <i>MLL-AF9</i>-Driven Acute Myeloid Leukemia
Authors: Maria Rodriguez Zabala, Ramprasad Ramakrishnan, Katrin Reinbach, Leal Oburoglu, Somadri Ghosh, Ton Falqués, Pablo Peña-Martínez, Noelia Puente-Moncada, Thoas Fioretos, Anna Hagstroem-Andersson, Niels-Bjarne Woods, Marcus Järås
Journal: Blood (2021)
Untethered Microrobots for Active Drug Delivery: From Rational Design to Clinical Settings
Authors: Dong Liu, Ting Wang, Yuan Lu
Journal: Advanced Healthcare Materials (2021)

Recent advances of untethered microrobots, which navigate the complex regions in vivo for therapeutics, have presented promising multiple applications on future healthcare. Microrobots used for active drug delivery system (DDS) have been demonstrated for advanced targeting distribution, improved delivery efficiency, and reduced systemic side effects. In this review, the therapeutic benefits of active DDS are presented compared to the traditional passive DDS, which illustrate the historical reasons for choosing active DDS. An integrated 5D radar chart analysis model containing the core capabilities of the active DDS is innovatively proposed. It would be a practical tool for measurement and mapping of the field of active delivery, followed by the evolutions and bottlenecks of each technical module. The comprehensive consideration of microrobots before clinical application is also discussed from the aspects of robot ethics, dosage, quality control and stability control in actual production. Gastrointestinal and blood administration, as two major clinical scenes of drug delivery, are discussed in detail as examples of the potential bedside applications of active DDS. Finally, combined with the reported analysis model, the current status and future outlook from the translation prospect to the clinical scenes of microrobots are provided.
Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
Authors: Efstathios Kastritis, Evangelos Terpos, Aimilia D. Sklirou, Foteini Theodorakakou, Despina Fotiou, Eleni-Dimitra Papanagnou, Tina Bagratuni, Nikolaos Kanellias, Magdalini Migkou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Ioanna Charitaki, Maria Gavriatopoulou, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos
Journal: Blood (2021)
Surgical Management of Mitral Regurgitation After Repair of Endocardial Cushion Defects
Authors: Adrian M. Moran, Sabine Daebritz, John F. Keane, John E. Mayer
Journal: Circulation (2000)

Background —Mitral regurgitation (MR) represents the principal indication for reoperation in patients after repair of atrioventricular septal defects (AVSD). Reports of mitral valvuloplasty (MVP) in such patients are few; the alternative, mitral valve replacement (MVR), necessitates commitment to future valve replacement and long-term anticoagulation. We sought to determine the outcome of those patients who underwent either MVP or MVR between January 1, 1988, and December 31, 1998, for significant MR after repair of AVSD. Furthermore, we sought to identify (a) morphological predictors necessitating MVR, and (b) predictors of future reoperation within the MVP group. Methods and Results —Retrospective review of clinical, operative, and echocardiographic data were performed. There were 46 patients identified (37 MVP and 9 MVR). The median age at initial AVSD repair was 0.6 years, and the age at subsequent mitral valve operation was 2.8 years. The early postoperative mortality rate was 2.2%, and survival at 1 and 10 years was 89.9% and 86.6%, respectively. A high rate of complete heart block was noted within the MVR group (37.5%). Freedom from later mitral valve reoperation for both groups was similar. No significant morphological predictors necessitating MVR were found. Predictors of reoperation within the MVP group included the presence of moderate or worse MR in the early postoperative period. In both groups New York Heart Association class, degree of MR, growth, and ventricular volumes improved. Conclusions —Mitral valve surgery significantly improves clinical status, with a sustained improvement in ventricular chamber size. MR can be successfully managed in patients after repair of AVSD independent of morphological type. Overall survival is acceptable, and further reoperation within the MVP group is influenced by early outcome of repair.
Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 "Booster" Vaccination - Observational Data from the LLS National Registry
Authors: Lee M Greenberger, Larry A Saltzman, Jonathon W Senefeld, Patrick W Johnson, Louis J DeGennaro, Gwen L Nichols
Journal: Blood (2021)
A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Authors: Alexandre Bazinet, Elias J. Jabbour, Hagop Kantarjian, Kelly S. Chien, Courtney D. DiNardo, Maro Ohanian, Naval Daver, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Koichi Takahashi, Lucia Masarova, Nicholas J. Short, Yesid Alvarado, Philip A. Thompson, Guillermo Montalban-Bravo, Musa Yilmaz, Farhad Ravandi, Steven M. Kornblau, Naveen Pemmaraju, Heather Schneider, Bailey Mirabella, Kiran Naqvi, Guillermo Garcia-Manero
Journal: Blood (2021)
Automated Peripheral Blood Cell Differentiation Using Artificial Intelligence - a Study with More Than 10,000 Routine Samples in a Specialized Leukemia Laboratory
Authors: Torsten Haferlach, Christian Pohlkamp, Inseok Heo, Rudolf Drescher, Siegfried Hänselmann, Thomas Lörch, Wolfgang Kern, Claudia Haferlach, Niroshan Nadarajah
Journal: Blood (2021)
Abstract 9586: Prognostic Impacts of Changes in Right Ventricular Fractional Area Change in Patients with Heart Failure
Authors: Yukiko Sugawara, Akiomi Yoshihisa, Ryohei Takeishi, Himika Ohara, Yasuhiro Ichijo, Yu Hotsuki, Koichiro Watanabe, Yu Sato, Satoshi Abe, Tomofumi Misaka, Takamasa Sato, Masayoshi Oikawa, ATSUSHI KOBAYASHI, Kazuhiko Nakazato, Yasuchika Takeishi
Journal: Circulation (2021)

Background: It has been reported that changes in left ventricular ejection fraction (LVEF) is associated with further prognosis in patients with heart failure (HF). We aimed to examine prognostic impact of changes in right ventricular fractional area change (RVFAC) on risk of cardiac event including cardiac death and worsening HF in HF patients. Methods and Results: We enrolled consecutive 480 hospitalized patients with decompensated HF and measured RVFAC with echocardiography at discharge (1 st examination) and post discharge in the outpatients setting (2 nd examination). RVFAC at 1 st examination of 480 HF patients were above 35% in 314 (65.4%), 25-35% in 108 (22.5%), and less than 25% in 58 (12.1%) patients. Next, based on RVFAC changes from 1 st to 2 nd examination, these patients were categorized into four groups: 1) U-preserved (unchanged and preserved-RVFAC, n=235, 49.0%); 2) Recovered-RVFAC (improvement in at least one category from 1 st to 2 nd examination, n=106, 22.1%); 3) U-reduced (unchanged and reduced-RVFAC, n=47, 9.8%); and 4) Worsened-RVFAC (deterioration of at least one category from 1 st to 2 nd examination, n=92, 19.2%). There was only a weak correlation between RVFAC change and LVEF change (R=0.16, P&lt;0.01). Multivariate logistic regression analysis revealed that anemia and chronic kidney disease were predictors of Worsened-RVFAC. In the Kaplan-Meier analysis ( Figure ), RVFAC at 1 st examination was not associated with cardiac event rate. However, RVFAC changes from 1 st to 2 nd examination was associated with cardiac event rate. In the multivariable Cox proportional hazard analysis, Worsened-RVFAC was an independent predictor of cardiac event rate (vs. U-preserved-RVFAC, HR 2.25, P&lt;0.01; vs. Recovered-RVFAC, HR 2.75, P&lt;0.01). Conclusions: The HF patients with worsened-RVFAC are associated with adverse prognosis. RVFAC changes are important for deciding treatment and predicting prognosis in HF patients.
Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study
Authors: Rasmus T. Hoeg, Anna Moroz, Arpita Gandhi, Lori Muffly, Parveen Shiraz, Caspian Oliai, Rohtesh S. Mehta, Samer A. Srour, Joseph P. McGuirk, Edmund K. Waller, Sally Arai, Laura J. Johnston, Robert Lowsky, Andrew R. Rezvani, Wen-Kai Weng, David B. Miklos, Matthew J. Frank, John Tamaresis, Ying Lu, Vaibhav Agrawal, Nathaniel B Fernhoff, Gerhard Bauer, Amy Putnam, J Scott McClellan, Bronwen E. Shaw, Mehrdad Abedi, Robert S. Negrin, Everett H Meyer
Journal: Blood (2021)
Price versus clinical guidelines in primary care statin prescribing: a retrospective cohort study and cost simulation model
Authors: Matias Ortiz De Zarate, Emmanouil Mentzakis, Simon DS Fraser, Paul Roderick, Paul Rutter, Carmine Ornaghi
Journal: Journal of the Royal Society of Medicine (2021)

To investigate the relative impact of generic entry and National Institute for Health and Care Excellence clinical guidelines on prescribing using statins as an exemplar.Retrospective analysis of statin prescribing in primary care and cost simulation model.Royal College of General Practitioners Research and Surveillance Centre (RCGP R&SC) database and Prescription Cost Analysis (PCA) database.New patients prescribed statins for the first time between July 2003 and September 2018.Shares of new patients prescribed one of the five statins available in the British National Formulary, and cost of prescribing statins to new and existing patients in primary care in England.General trends of statin' prescriptions were largely driven by a decrease in acquisition costs triggered by patent expiration, preceding NICE guidelines which themselves did not seem to affect prescription trends. Significant heterogeneity is observed in the prescription of the most cost-effective statin acrossGPs. A cost simulation shows that, between 2004 and 2018, the NHS could have saved £2.8bn (around 40% of the £6.3bn spent on statins during this time) if all GP practices had prescribed only the most cost-effective treatment.There is potential for large savings for the NHS if new and, whenever possible, ongoing patients are promptly switched to the first medicine that becomes available as generic within a therapeutic class as long as it has similar efficacy to still-patented medicines.
The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma
Authors: Fabio Efficace, Gianluca Gaidano, Maria Teresa Petrucci, Pasquale Niscola, Lucia Tognazzi, Elisabetta Antonioli, Francesco Cottone, Ombretta Annibali, Agostino Tafuri, Catello Califano, Alessandra Larocca, Leonardo Potenza, Giulia Palazzo, Claudio Fozza, Domenico Pastore, Gian Matteo Rigolin, Massimo Offidani, Alessandra Romano, Patrizia Tosi, Charalampia Kyriakou, Nicola Cascavilla, Stefano Molica, Alessandro Gozzetti, Daniele Derudas, Marco Vignetti, Michele Cavo
Journal: Blood (2021)
Experiences of Sickle Cell Disease (SCD) Reported By Healthcare Professionals (HCPs) across Different Regions: International Sickle Cell World Assessment Survey (SWAY)
Authors: Ifeyinwa Osunkwo, Biree Andemariam, Caterina P Minniti, Fuad El Rassi, Erfan Nur, Alecia C Nero, Raffaella Colombatti, Mariane de Montalembert, Miguel R Abboud, Jean-Benoît Arlet, Suman Jain, Wasil Jastaniah, Marimilia Pita, Beverley Francis-Gibson, Cassandra Trimnell, Laurie DeBonnett, Tom Bailey, Olivera Rajkovic-Hooley, Baba PD Inusa, John James
Journal: Blood (2021)
The Spatial Heterogeneity in Newly Diagnosed Multiple Myeloma Patients - from Sub-Clonal Architecture to the Immune Microenvironment
Authors: Lukas John, Alexandra Poos, Stephan M Tirier, Jan-Philipp Mallm, Nina Prokoph, Alexander Brobeil, Raphael Lutz, Sabrina Schumacher, Simon Steiger, Katharina Bauer, Anja Baumann, Christoph Rehnitz, Carsten Müller-Tidow, Hartmut Goldschmidt, Stefanie Huhn, Karsten Rippe, Marc-Steffen Raab, Sandra Sauer, Niels Weinhold
Journal: Blood (2021)
Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL
Authors: Swati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, Manik Kuvalekar, Ayumi Watanabe, Catherine Robertson, Adrian P. Gee, Bambi J. Grilley, George Carrum, Rammurti Kamble, LaQuisa C. Hill, Robert A. Krance, Caridad A. Martinez, Bilal Omer, Stephen Gottschalk, Helen E. Heslop, Cliona M. Rooney, Juan Vera, Ann Leen, Premal D. Lulla
Journal: Blood (2021)
Abstract 13067: Recapitulating Long QT Syndrome Phenotype in Induced Pluripotent Stem Cells-Derived Cardiomyocytes Using CRISPR/Cas9 Technology
Authors: Ning Ge, MIN LIU, Janusz Krawczyk, veronica mcinerney, Joseph Galvin, Deirdre Ward, Catherine McGorrian, Timothy O'Brien, Sanbing Shen, Terence W Prendiville
Journal: Circulation (2021)

Introduction: Long QT syndrome (LQTS) is an inherited arrhythmia syndrome with a hallmark of QT prolongation secondary to delayed repolarization of cardiomyocytes (CM) on 12-lead ECG. Hypothesis: Studying LQTS in an induced pluripotent stem cell (iPSC)-derived CM model allows for patient-specific phenotype characterization in vitro . We report such a strategy (fig. A) in a patient with LQT type 3 (ECG QTc 503 msec) who harbored a heterozygous pathogenic variant in SCN5A (c.1231G&gt;A), and in a healthy control for comparison (ECG QTc 388 msec). Methods: IPSCs were generated from patient and control dermal fibroblasts using a non-integrational Sendai reprogramming method. The patient’s SCN5A (c.1231G&gt;A) variant was edited into the healthy control using CRISPR/Cas9 technology. CM were subsequently differentiated and beating CM clusters were seeded onto Maestro CytoView multi-electrode array plates. Serial corrected field potential duration (FPD) measurements (n=12), equivalent to QTc values on ECG, were recorded on days 24 to 39 of CM differentiation per sample. CM were exposed to varying concentrations of Nifedipine and Sotalol through cell culture media exchange. Paired t-tests (non-parametric) were utilized for p&lt;0.05. Results: Reprogrammed iPSCs displayed pluripotency characteristics (fig.B). IPSC-derived CMs had confirmed cardiac lineage (fig. C). Prolonged FPD values, corrected for beating rate, were observed in both the LQT3 patient-derived iPSC-CMs (p&lt;0.0001) and the genetically induced LQT3 iPSC-CMs (p&lt;0.0001) compared to control (fig. D &amp; E). Nifedipine and sotalol altered FPD in a dose-dependent response (fig. F &amp; G). Conclusions: An iPSC-derived CM model reliably recapitulates the phenotype of LQTS. Induced LQT3 iPSC-CMs genetically edited from a healthy control accurately recapitulate the LQT3 disease phenotype. Drug effects on CM repolarization were demonstrable in the iPSC-CM model.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Authors: Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Sven De Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Francisco Hernandez-Ilizaliturri, Eric Hsi, Boyu Hu, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Megan Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar
Journal: Journal of the National Comprehensive Cancer Network (2021)

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
Immunomodulation with Romiplostim in Young Adult Primary Immune Thrombocytopenia (ITP) As Second-Line Strategy (iROM-study)
Authors: Alexandra Schifferli, Axel Rüfer, Alicia Rovo, Nathan Cantoni, Andreas Holbro, Geneviève Favre, Heike Faeth, Renata Rosa Pereira, Anna Wieland, Jan Dirks, Falk Nimmerjahn, Thomas Kuehne
Journal: Blood (2021)
<i>KMT2A</i> Partial Tandem Duplications (<i>KMT2A</i>-PTD) Is a Rare, but Recurrent Genomic Event in Childhood AML and Associated with High Rate of Co-Occurring <i>FLT3</i> Mutations
Authors: Danielle C. Kirkey, Katherine Tarlock, Rhonda E. Ries, Yi-Cheng Wang, Amanda R. Leonti, Quy Le, Jenny L. Smith, Leila Robinson, Yanling Liu, Quang Tran, Richard Aplenc, Jessica A. Pollard, Anders E. Kolb, Todd A. Alonzo, Xiaotu Ma, Soheil Meshinchi
Journal: Blood (2021)
Abstract 10892: Cross-Cultural Validation and Psychometric Testing of the Heart Failure Somatic Perception Scale in Japan
Authors: KANAKO HAYASHI, Akiko Okada, Corrine Y Jurgens, Shinya Ito, Miyuki Tsuchihashi-makaya
Journal: Circulation (2021)

Background: The assessment of symptoms experienced by patients with heart failure (HF) has important contextual implications for self-care and allows for early recognition of signs of worsening HF. The Heart Failure Somatic Perception Scale (HFSPS) is a measurement tool developed in the U.S. to assess symptoms experienced by patients with HF, but it is expected to be applicable to patients in countries with different cultural backgrounds. Objectives: To evaluate the psychometric properties (validity and reliability) of the HFSPS in Japanese HF patients. Methods: This study assessed the factor structure of the HFSPS using confirmatory factor analysis in 320 HF outpatients in Japan. Criterion-related validity of the HFSPS was evaluated by correlating its factor scores with Patient-Reported Outcomes Measurement Information System (PROMIS) scores using Pearson's correlation coefficient. Internal consistency reliability of the HFSPS was evaluated using the factor score coefficient of determination, Cronbach's alpha, and the model-based internal consistency index. Results: The sample (n=320) was 72% male, mean age 72.9±12.8 years. Confirmatory factor analysis examining the four-factor structure of the HFSPS (dyspnea, chest discomfort, early and subtle, and edema), resulted in resulted in the following fit indices: χ2= (129, N=310), P&lt;0.001, comparative fit index =0.825, Tucker-Lewis index =0.793, root mean square error of approximation =0.131. For criterion-related validity, all domains of the PROMIS items (physical health, mental health, global health, and social role satisfaction) were negatively correlated (-0.07 to -0.37) and statistically significant indicating higher symptom burden was associated with worse global health. HFSPS reliability resulted in Cronbach's alpha 0.878 for dyspnea, 0.607 for chest discomfort, 0.772 for early and subtle, 0.777 for edema, and 0.921 for the entire scale. Conclusion: This study suggests the HFSPS is a reliable and valid tool among Japanese with HF. Using this scale will provide accurate assessment of symptoms experienced by HF patients in research testing educational interventions to improve HF symptom recognition and response.
Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific Dart® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia
Authors: Ralph F. Alderson, Ling Huang, Xiaoyu Zhang, Haiquan Li, Thomas Kaufman, Gundo Diedrich, Paul Moore, Ezio Bonvini
Journal: Blood (2021)
Lesson of the Week: Adrenal mass with virilisation: importance of endocrine investigation
Authors: J. Nasir, C. Walton
Journal: BMJ (1996)

For people who have complex disability or multiple medical problems, respite at a day hospital or in a hos- pital bed might be more appropriate than care in their own home or a residential home.This can be arranged by the local hospital department of elderly medicine after referral by a general practitioner.Types of respite care provided by social services departments * Sitting service * Day centre attendance * Family placement schemes * Respite in residential or nursing home Services for elderly people with sensory impairmentLocal social services departments hold a register of blind and partially sighted people.Registration is voluntary, and follows referral to and examination by an ophthalmologist.Rehabilitation officers for visually handicapped people work as members of the disability services team and can give advice to help a person with impaired vision cope with the activities of daily living.This may include training in communication methods and techniques to improve mobility, and special equipment (for example clocks, telephones) may be provided.Social services rehabilitation officers also act as a link with voluntary services for visually impaired or deaf people.Social services departments or voluntary bodies may run day centres for partially sighted or blind people and deaf people; local authority homes that specialise in the care of visually impaired people are found in some areas.Further reading
Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma
Authors: Yuting Yan, Xiaoqi Qin, Jiahui Liu, Huishou Fan, Lanting Liu, Zhen Yu, Shuhui Deng, Wei Liu, Dehui Zou, Lugui Qiu, Gang An
Journal: Blood (2021)
Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial
Authors: Zachary D. Crees, Keith E. Stockerl-Goldstein, Sarah Larson, Árpád Illés, Giuseppe Milone, Massimo Martino, Patrick Stiff, Douglas W. Sborov, Denise L. Pereira, Ivana N. Micallef, Gemma Moreno Jiménez, Gábor Mikala, Maria liz paciello Coronel, Udo Holtick, John W. Hiemenz, Muzaffar H. Qazilbash, Nancy M. Hardy, Tahir Latif, Irene García-Cadenas, Abi Vainstein, Ella Sorani, Irit Gliko-Kabir, Inbal Goldstein, Shaul Kadosh, John F. DiPersio
Journal: Blood (2021)